关于临床试验中的潜在治疗干预危害的公众观点 - 术语和沟通
Rachel Phillips1, Dongquan Bi2, Beatriz Goulão3
1Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK. r.phillips@imperial.ac.uk.
Trials
|August 30, 2024
概括
关于临床试验术语的公众意见建议广泛使用"副作用"和严重事件的"伤害". 需要在公共材料中进行更清晰的沟通,以防止有关干预风险的误解.
科学领域:
- 临床研究方法论临床研究方法论
- 患者和公众参与.
- 卫生沟通健康沟通
背景情况:
- 随机对照试验 (RCT) 评估干预的好处和风险.
- 试验中有害影响的术语不一致 (例如,不良事件,伤害结果,安全结果) 会使沟通复杂化.
- 复杂干预中的有害影响被用各种各样的词汇描述,比如"意外后果".
研究的目的:
- 收集关于临床试验中干预损害的首选术语的公众意见.
- 了解公众对试验危害如何在科学文献和公共材料中传播的观点.
- 确定潜在的改进,以更清楚地沟通干预风险.
主要方法:
- 在2023年在伦敦和阿伯丁举行了两次面对面的公众参与会议.
- 提供了关于在临床试验中收集和呈现危害数据的背景信息.
- 促进了关于术语的讨论和干预危害的沟通.
主要成果:
- 公共合作伙伴更喜欢一般使用的"副作用"和严重事件的"伤害".
- 参与者通常对面向公众的材料感到满意,但注意到来自NHS网站信息的误解.
- 对于不同的情况,不同的术语得到了认可,这表明需要细微的沟通.
结论:
- 这项研究为患者喜欢的术语提供了一个起点,关于干预的危害.
- 公共合作伙伴主张使用特定上下文的语言,而不是单一的协调术语.
- 改善面向公众的材料至关重要,以防止错误的沟通和对伤害的误解.
相关概念视频
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Hazard Ratio
99
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
99
Blinding
2.4K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.4K
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789


